CFO THOUGHT LEADER
Bonus Replay: How a Biotech Disrupter Is De-risking R&D | Jamey Mock, CFO, Moderna
Nov 27, 2024
Jamey Mock, CFO of Moderna and a key figure in biotechnology, discusses how the company is diversifying its R&D efforts with over 40 drugs in the pipeline. He explains the innovative use of mRNA technology that allows for quick reprogramming, reducing risks in drug development. The conversation also touches on Moderna's strategic shift beyond COVID-19, the role of AI in enhancing drug production, and the importance of clear communication with investors regarding progress in trials.
43:12
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- Moderna's diversified R&D pipeline of over 40 drugs reduces reliance on single products, enhancing overall risk management strategies.
- The innovative use of mRNA technology allows Moderna to quickly adapt its therapeutic targets, significantly increasing the likelihood of successful outcomes.
Deep dives
Investment in R&D Growth
Moderna significantly increased its investment in research and development (R&D), ramping spending to nearly $5 billion this year, a substantial rise from $500 million in 2019. This expansion aligns with the company's strategy to bring several new drugs to market quickly, with an ambitious goal of launching four to five drugs by 2025 and 15 by 2028. The increased funding is viewed as necessary due to the anticipated decline in COVID vaccine volumes, prompting a pivot towards broader therapeutic innovations. Moderna's robust financial positioning allows for such strategic investments, positioning the company to capitalize on its potential in various disease areas.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
